Misplaced Pages

Mufemilast

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Pharmaceutical compound
Mufemilast
Clinical data
Other namesHemay005
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • N--4,6-dioxothienopyrrol-3-yl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC20H22N2O7S2
Molar mass466.52 g·mol
3D model (JSmol)
SMILES
  • CCOC1=C(C=CC(=C1)(CS(=O)(=O)C)N2C(=O)C3=CSC(=C3C2=O)NC(=O)C)OC
InChI
  • InChI=1S/C20H22N2O7S2/c1-5-29-16-8-12(6-7-15(16)28-3)14(10-31(4,26)27)22-19(24)13-9-30-18(21-11(2)23)17(13)20(22)25/h6-9,14H,5,10H2,1-4H3,(H,21,23)/t14-/m1/s1
  • Key:PRSNGWLHNWGOKD-CQSZACIVSA-N

Mufemilast (Hemay005) is a small-molecule inhibitor of phosphodiesterase 4. It is developed by Hemay Pharmaceutical for psoriasis.

References

  1. Liu, Xuemei; Chen, Rui; Zeng, Guanghuai; Gao, Ying; Liu, Xiuping; Zhang, Donglei; Hu, Pei; Wang, Hongyun; Jiang, Ji (1 June 2018). "Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study". Bioanalysis. 10 (11): 863–875. doi:10.4155/bio-2018-0004. ISSN 1757-6199. PMID 29863892. S2CID 46929693.
  2. Tomar, Yashika; Gorantla, Srividya; Singhvi, Gautam (February 2023). "Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches". Drug Discovery Today. 28 (2): 103465. doi:10.1016/j.drudis.2022.103465. PMID 36481585. S2CID 254304811.
  3. Claudia, Cervantes-Durán; María-Elena, Velázquez-Hernández; Josué, Valentín-Escalera; María-Carmen, Bartolomé-Camacho; Alain-Raimundo, Rodríguez-Orozco; Martha-Estrella, García-Pérez (November 2020). "Small molecules under development for psoriasis: on the road to the individualized therapies". Archives of Dermatological Research. 312 (9): 611–627. doi:10.1007/s00403-020-02056-3. PMID 32172339. S2CID 212706837.
Categories: